Company intelligence / Profile preview

DOC Pharma

Italy

Ownership: Private
Development stage: Other

Overview

DOC Pharma is a leading independent pharmaceutical company specializing in generic medicines, with commercialized products in cardiovascular, gastrointestinal and metabolic, ophthalmology, anti-infective, and oncology/immunomodulatory areas[2][3][5]. The company has been repeatedly acquired but maintains independence, focusing on manufacturing in Italy and expanding through strategic acquisitions and product portfolio additions[2]. Approximately 73% of DOC Pharma products are made in Italy, supporting local supply chains and accessibility[3].

Therapeutic areas: CardiovascularOphthalmologyRheumatologyInfectious DiseasesNeurologyMetabolic DisordersOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Chiesi FarmaceuticiZambonApotex

Beyond the preview

Go deeper on DOC Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DOC Pharma.

Explore the full profile